A detailed history of Man Group PLC transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Man Group PLC holds 76,227 shares of BGNE stock, worth $13.5 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
76,227
Previous 9,177 730.63%
Holding current value
$13.5 Million
Previous $1.31 Million 1207.33%
% of portfolio
0.05%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$143.93 - $224.51 $9.65 Million - $15.1 Million
67,050 Added 730.63%
76,227 $17.1 Million
Q2 2024

Aug 14, 2024

BUY
$129.52 - $174.32 $303,335 - $408,257
2,342 Added 34.26%
9,177 $1.31 Million
Q1 2024

May 15, 2024

SELL
$141.8 - $181.47 $4.86 Million - $6.23 Million
-34,308 Reduced 83.39%
6,835 $1.07 Million
Q4 2023

Feb 14, 2024

BUY
$158.67 - $201.58 $6.53 Million - $8.29 Million
41,143 New
41,143 $7.42 Million

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $18.4B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Man Group PLC Portfolio

Follow Man Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.